In this phase 3 , double-blind , randomized , controlled trial , we randomly assigned , in a 1:1 ratio , 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months .